BOCH
AKTS

Blue Owl Capital Holdings’s Aktis Oncology AKTS Stock Holding History

Blue Owl Capital Holdings’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99M Sell
3,070,219
-91,129
-3% -$1.87M 14.89% 2
2026
Q1 		$56.6M Buy
+3,161,348
New +$61.4M 15.2% 1

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Blue Owl Capital Holdings's AKTS Position: Q2 2026 in Review

Blue Owl Capital Holdings reduced its Aktis Oncology (AKTS) stake by 2.9% in Q2 2026, selling an estimated $1.87M and leaving 3,070,219 shares worth $99M. The position accounts for 14.89% of the portfolio, ranked #2.

Blue Owl Capital Holdings first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • Blue Owl Capital Holdings held 3,070,219 shares of Aktis Oncology worth $99M as of Q2 2026.
  • Blue Owl Capital Holdings sold 91,129 Aktis Oncology shares in Q2 2026, an estimated $1.87M.
  • Aktis Oncology made up 14.89% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #2 holding.
  • Blue Owl Capital Holdings first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.